A novel chemically modified analogue of xenin-25 exhibits improved glucose-lowering and insulin-releasing properties.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
Parthsarathy, Vadivel
Irwin, Nigel
Hasib, Annie
Martin, Christine M.
McClean, Stephen
Bhat, Vikas K.
NG, Ming T.
Flatt, Peter R.
Gault, Victor A.
Issue Date
2016-01-21
Metadata
Show full item recordAbstract
BACKGROUND: Xenin-25 is a K-cell derived gut peptide with insulin-releasing activity which is rapidly degraded following release into the circulation. We hypothesized that substitution of all naturally-occurring Lys and Arg residues with Gln would lead to prolonged enzyme resistance and enhanced biological efficacy.METHODS: Peptide stability was assessed using murine plasma, in vitro insulin-releasing actions evaluated in BRIN-BD11 cells and acute glucose-lowering and insulin-releasing actions examined in high fat fed mice. For sub-chronic studies, a range of metabolic parameters and pancreatic histology were assessed in high fat fed mice which had received saline vehicle or xenin-25(gln) twice-daily for 21days.RESULTS: In contrast to native xenin-25, xenin-25(gln) was resistant to plasma-mediated degradation and significantly stimulated insulin secretion in BRIN-BD11 cells. Acute administration of xenin-25(gln) in high fat fed mice significantly reduced blood glucose and increased plasma insulin concentrations. Twice-daily administration of xenin-25(gln) in high fat fed mice did not affect food intake, body weight or circulating insulin concentrations but significantly decreased blood glucose from day 9 onwards. Furthermore, glucose tolerance, glucose-mediated insulin secretion, insulin sensitivity and GIP-stimulated insulin-release were significantly enhanced in xenin-25(gln)-treated mice. Pancreatic immunohistochemistry revealed decreased alpha cell area with increased beta cell area and beta-to-alpha cell ratio in xenin-25(gln)-treated mice. In addition, xenin-25(gln) exerted similar beneficial actions in ob/ob mice as demonstrated by reduced blood glucose, superior glycaemic response and glucose-mediated insulin release.CONCLUSIONS: Xenin-25(gln) is resistant to plasma-mediated degradation and exerts sustained and beneficial metabolic actions in high fat fed and ob/ob mice.GENERAL SIGNIFICANCE: Glutamine (gln)-modified analogues of xenin may represent an attractive therapeutic approach for type 2 diabetes.Citation
Parthsarathy, Vadivel, Irwin, Nigel, Hasib, A, Martin, CM, McClean, Stephen, Bhat, VK, NG, Tony, Flatt, Peter and Gault, Victor A (2016) A novel chemically modified analogue of xenin-25 exhibits improved glucose-lowering and insulin-releasing properties. Biochimica et Biophysica Acta, 1860 (4). pp. 757-764.Publisher
ElsevierJournal
Biochimica et Biophysica ActaDOI
10.1016/j.bbagen.2016.01.015Additional Links
http://uir.ulster.ac.uk/33791/Type
Journal articleISSN
0304-4165ae974a485f413a2113503eed53cd6c53
10.1016/j.bbagen.2016.01.015